文献速递药物相互作用

替万替尼对CYP酶及P-糖蛋白探针药物药代动力学影响的评价

Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours.
PubMed 文献 · Br J Clin Pharmacol · 2017-10-29

本研究为1期开放标签交叉试验,在28例晚期实体瘤患者中使用鸡尾酒探针法评估替万替尼360 mg每日两次对CYP1A2、CYP2C9、CYP2C19、CYP3A4及P-糖蛋白底物药代动力学的影响。结果显示替万替尼对CYP探针药物影响极小或无影响,但降低P-糖蛋白底物地高辛的系统暴露。

要点

  • 替万替尼360 mg每日两次对CYP1A2、CYP2C9、CYP2C19、CYP3A4底物药代动力学影响极小或无影响。
  • 替万替尼降低P-糖蛋白底物地高辛的系统暴露,AUC比值为0.69(90%CI 0.51-0.94)。
  • 临床合用P-糖蛋白底物时需关注暴露降低可能影响疗效。

核心结论

  • 替万替尼360 mg每日两次对CYP1A2、CYP2C9、CYP2C19和CYP3A4底物探针药物的药代动力学影响极小或无影响。
  • 替万替尼降低P-糖蛋白底物地高辛的系统暴露。

研究设计与样本

  • 1期、开放标签、交叉研究,在28例晚期癌症患者中使用鸡尾酒探针法。
  • 患者单次单独接受探针药物,并在替万替尼360 mg每日两次治疗5天后再次接受探针药物。

主要发现

  • 替万替尼存在/不存在时AUClast几何最小二乘均值比值(90%CI):咖啡因0.97(0.89-1.05)、S-华法林0.88(0.76-1.02)、奥美拉唑0.89(0.60-1.31)、咪达唑仑0.83(0.67-1.02)、地高辛0.69(0.51-0.94)。
  • Cmax比值类似,地高辛存在/不存在时Cmax比值为0.75(0.60-0.95)。

关键数值与推荐

  • CYP1A2探针为咖啡因,CYP2C9探针为S-华法林,CYP2C19探针为奥美拉唑,CYP3A4探针为咪达唑仑,P-糖蛋白探针为地高辛。
  • 替万替尼剂量为360 mg每日两次,治疗5天后进行探针药物评估。

临床怎么用

  • 与CYP1A2、CYP2C9、CYP2C19、CYP3A4底物合用时预计无需常规剂量调整。
  • 与P-糖蛋白底物(如地高辛)合用时需警惕底物暴露降低,应监测疗效或考虑调整剂量。

局限性

  • 研究为1期开放标签交叉设计,样本量28例。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: This phase 1, open-label, crossover study sought to evaluate drug-drug interactions between tivantinib and cytochrome P450 (CYP) substrates and tivantinib and P-glycoprotein. METHODS: The effect of tivantinib doses on the pharmacokinetics of the probe drugs for CYP1A2 (caffeine), CYP2C9 (S-warfarin), CYP2C19 (omeprazole), and CYP3A4 (midazolam), and for P-glycoprotein (digoxin) was investigated in 28 patients with advanced cancer using a cocktail probe approach. Patients received single doses of probe drugs alone and, after 5 days of treatment, with tivantinib 360 mg twice daily. RESULTS: The ratios of geometric least squares mean (90% confidence interval) for the area under the concentration-time curve from time zero to the last quantifiable concentration in the presence/absence of tivantinib were 0.97 (0.89-1.05) for caffeine, 0.88 (0.76-1.02) for S-warfarin, 0.89 (0.60-1.31) for omeprazole, 0.83 (0.67-1.02) for midazolam, and 0.69 (0.51-0.94) for digoxin. Similar effects were observed for maximum plasma concentrations; the ratio for digoxin in the presence/absence of tivantinib was 0.75 (0.60-0.95). CONCLUSIONS: The data suggest that tivantinib 360 mg twice daily has either a minimal or no effect on the pharmacokinetics of probe drugs for CYP1A2, CYP2C9, CYP2C19 and CYP3A4 substrates, and decreases the systemic exposure of P-glycoprotein substrates when administered with tivantinib.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Tachibana M, Papadopoulos KP, Strickler JH, et al. Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours. Br J Clin Pharmacol. 2017. PMID: 28865153. doi:10.1111/bcp.13424

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。